Skin Hives Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Chronic Hives, Acute Hives), By Treatment (Anti-Inflammatory Drugs, Anti-Itch Drugs, Antihistamines, Others), By Route of Administration (Oral, Topical, Parenteral), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Region and Competition, 2020-2030F

Market Overview

The Global Skin Hives Treatment Market, valued at USD 2.98 Billion in 2024, is projected to experience a CAGR of 8.10% to reach USD 4.76 Billion by 2030. The Global Skin Hives Treatment Market comprises pharmaceutical interventions and therapeutic modalities aimed at managing symptoms of urticaria, characterized by itchy wheals and angioedema affecting dermal layers. Market growth is primarily driven by the increasing global incidence of allergic conditions and heightened public awareness of these dermatological issues. Furthermore, continuous advancements in diagnostic capabilities and the introduction of advanced treatment options, including novel antihistamine formulations and biologic agents, fuel market progression.

According to the American Academy of Pediatrics, over 20 million children in the U. S. received antihistamine treatments in 2023. A significant challenge that could impede market expansion is the prevalent issue of underdiagnosis and the refractory nature of chronic forms of urticaria, which often necessitate complex and prolonged treatment regimens, thereby affecting patient adherence and healthcare resource allocation.

Key Market Drivers

The increasing global prevalence of allergic skin conditions represents a fundamental driver for the Global Skin Hives Treatment Market, directly expanding the patient population requiring therapeutic interventions. Urticaria, characterized by intensely itchy wheals, is a significant component of this rising burden. This escalating incidence creates a continuous demand for effective diagnostic and treatment solutions across all demographic segments. For example, according to a study published in "Global, regional, and National burden of urticaria (1990–2021), its potential risk factors, and projections to 2046", in August 2025, the global burden of urticaria reached 66.48 million cases in 2021, underscoring the growing patient pool that necessitates medical management.

Furthermore, advancements in pharmacological treatments and biologics profoundly shape market dynamics by introducing more effective and targeted therapies. These innovations not only improve patient outcomes, particularly for chronic or refractory cases, but also address previously unmet medical needs. The development and approval of novel agents, including sophisticated antihistamine formulations and biologic medications, provide clinicians with a broader arsenal against this debilitating condition. A pivotal example is seen in the recent regulatory landscape, where, according to Dermatology Times, in April 2025, the US FDA approved dupilumab for chronic spontaneous urticaria, marking the first new targeted therapy for the condition in over a decade. This approval directly benefits more than 300,000 patients in the US with inadequately controlled disease. The investment in such innovative therapies reflects the market's response to rising patient needs, as evidenced by the high cost of new treatments; according to Pharmaphorum, in October 2025, Novartis announced that remibrutinib, an oral BTK inhibitor, will cost $4,521 for a 30-day supply at list prices.

Download Free Sample Report

Key Market Challenges

The prevalent issue of underdiagnosis and the refractory nature of chronic urticaria significantly impedes the growth of the Global Skin Hives Treatment Market. Underdiagnosis prevents numerous individuals suffering from urticaria from receiving appropriate medical care, thus limiting their entry into the treatment pathway. This directly translates to a smaller addressable patient population for pharmaceutical interventions and therapeutic modalities.

Furthermore, for diagnosed patients, the refractory nature of chronic urticaria often necessitates complex and prolonged treatment regimens. This can lead to decreased patient adherence due to the burden of managing persistent symptoms despite initial treatments and the complexity of multi-drug protocols. According to the American Academy of Allergy, Asthma, & Immunology (AAAAI), in a study presented in 2025, approximately 55.9% of patients receiving omalizumab for chronic spontaneous urticaria required add-on therapies, and 26.2% utilized doses exceeding FDA-approved levels. Such protracted and often ineffective initial treatments strain healthcare resources and can discourage patients, thereby restricting market expansion by reducing the uptake and continuation of advanced treatment options.

Key Market Trends

The integration of digital health and telemedicine platforms is reshaping skin hives treatment through enhanced accessibility and continuous care. These platforms enable remote consultations, symptom monitoring, and personalized patient education, crucial for chronic urticaria management. This trend overcomes geographical barriers, improving patient convenience and fostering better treatment adherence. According to a survey by the American Academy of Dermatology, in August 2024, 67% of dermatologists anticipated practicing teledermatology weekly. Telemedicine also facilitates timely interventions and therapy adjustments via real-time patient data tracking. In February 2024, a *Journal of Drugs in Dermatology* study indicated dermatologists' use of teledermatology correlated with adoption time, broadening specialized expertise.

The introduction of biosimilar treatment options significantly impacts the Global Skin Hives Treatment Market by expanding access to biologic therapies and fostering competitive pricing. Biosimilars, offering comparable efficacy and safety to their reference biologics at lower costs, alleviate financial burdens on healthcare systems and patients. This increased affordability drives higher patient uptake and wider utilization of advanced therapies for chronic urticaria. According to the Generics and Biosimilars Initiative, as of July 2024, biosimilars had generated US$23.6 billion in savings in the US healthcare system since their introduction in 2015. This competitive pressure encourages innovation, making high-cost treatments more sustainable. For instance, in May 2024, Celltrion announced marketing authorization from the European Commission for Omlyclo, an omalizumab biosimilar approved for chronic spontaneous urticaria.

Segmental Insights

The Antihistamines segment is demonstrating rapid growth within the Global Skin Hives Treatment Market, primarily driven by their well-established efficacy, widespread availability, and affordability in addressing common urticaria symptoms. These medications effectively block histamine receptors, thereby mitigating itching, swelling, and discomfort associated with hives. The convenience of oral administration further enhances patient accessibility, making them a preferred first-line treatment option for both acute and mild chronic urticaria. The increasing global incidence of allergic disorders and urticaria, coupled with rising awareness and demand for effective and swift symptom relief, continues to propel the expansion of this segment in the market.

Regional Insights

North America leads the global skin hives treatment market due to several distinct factors. The region benefits from highly developed healthcare infrastructure and significant healthcare spending, which fosters extensive research and development activities for innovative treatments. A high prevalence of allergic conditions, including chronic urticaria, also contributes to a large patient population seeking effective remedies. Furthermore, the strong presence of major pharmaceutical companies and their continuous focus on drug development, along with high disease awareness and widespread availability of diverse treatment options, including advanced biologics, underpin North America's dominance in this market.

Recent Developments

• In September 2025, Novartis announced that Rhapsido (remibrutinib) received U.S. Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU). This medication is indicated for individuals who remain symptomatic despite H1 antihistamine treatment. Rhapsido, a Bruton's tyrosine kinase inhibitor (BTKi), works by targeting BTK to inhibit the release of histamine and other proinflammatory mediators, offering a novel approach to CSU management. The oral, twice-daily pill does not require injections or lab monitoring, providing a convenient option for patients in the global skin hives treatment market.

• In April 2025, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab), jointly developed by Regeneron Pharmaceuticals, Inc. and Sanofi, for treating adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU). This approval applies to individuals whose symptoms persist despite histamine-1 (H1) antihistamine treatment. Dupixent represents the first new targeted therapy for CSU in over a decade, with pivotal Phase 3 trials demonstrating significant reductions in itch and hives compared to placebo. This development offers a new treatment option for the more than 300,000 U.S. patients living with inadequately controlled CSU.

• In December 2024, Sunshine Biopharma Inc., through its wholly-owned Canadian subsidiary Nora Pharma Inc., launched a new generic prescription drug in Canada. The new product, Bilastine, is a generic version of Blexten® and is indicated for the relief of allergy symptoms, including urticaria, commonly known as hives. Bilastine is a second-generation antihistamine used for the treatment of allergic rhinitis and urticaria. This launch expands Nora Pharma's presence in the Canadian generic drugs market and offers an additional option for managing skin hives.

• In July 2024, Celldex Therapeutics, Inc. initiated its global Phase 3 clinical program for barzolvolimab in adult patients with chronic spontaneous urticaria (CSU). The program consists of two Phase 3 trials, EMBARQ-CSU1 and EMBARQ-CSU2, designed to evaluate the efficacy and safety of barzolvolimab. These studies include patients who remain symptomatic despite H1 antihistamine treatment, as well as those who have not responded adequately to prior biologic therapies. Barzolvolimab is a novel monoclonal antibody that targets the KIT receptor, aiming to inhibit mast cell function and survival, which are key drivers of CSU.

Key Market Players

• Otsuka Holdings Co., Ltd
• Taiho Pharmaceutical Co., Ltd
• Amneal Pharmaceuticals LLC
• Galderma SA
• F. Hoffmann-La Roche AG
• Novartis AG
• Dr. Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals Ltd.
• Sanofi SA

Report Scope:

In this report, the Global Skin Hives Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Skin Hives Treatment Market, By Type:

o   Chronic Hives

o   Acute Hives

• Skin Hives Treatment Market, By Treatment:

o   Anti-Inflammatory Drugs

o   Anti-Itch Drugs

o   Antihistamines

o   Others

• Skin Hives Treatment Market, By Route of Administration:

o   Oral

o   Topical

o   Parenteral

• Skin Hives Treatment Market, By Distribution Channel:

o   Hospital Pharmacies

o   Online Pharmacies

o   Retail Pharmacies

• Skin Hives Treatment Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Skin Hives Treatment Market.

Available Customizations:

Global Skin Hives Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Skin Hives Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]